Full Press Release Details
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT.
SLDB
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Key Takeaway: Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT